U.S. Markets closed

Tesaro, Inc. (TSRO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
153.1900-2.54 (-1.63%)
At close: 4:00PM EDT

153.7968 0.61 (0.40%)
After hours: 4:32PM EDT

People also watch
CLVSKITEPBYIPTLAAGIO
Interactive chart
Previous Close155.7300
Open157.2900
Bid140.1200 x 300
Ask153.4000 x 200
Day's Range152.8600 - 159.2500
52 Week Range36.7100 - 192.9400
Volume630,690
Avg. Volume983,235
Market Cap8.25B
Beta2.35
PE Ratio (TTM)-17.97
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments
    Investor's Business Daily7 days ago

    Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments

    Preliminary data highlights breast, ovarian, lung and skin cancer data to presented during the American Society of Clinical Oncology meeting next month.

  • Capital Cube7 days ago

    TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : May 18, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives TESARO, Inc. a score of 25. Our analysis is based on comparing TESARO, Inc. with the following peers – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Cerulean Pharma, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, CERU-US, ... Read more (Read more...)

  • Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?
    Investor's Business Daily8 days ago

    Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?

    An analyst upgraded Clovis ahead of a key study for its ovarian cancer drug, which he said holds up against another from AstraZeneca.